guest ::
| Home > Publications Database > Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome. > print |
| Home > Publications Database > Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome. > print |
| 001 | 282550 | ||
| 005 | 20251218103441.0 | ||
| 024 | 7 | _ | |a 10.1007/s00406-025-02013-z |2 doi |
| 024 | 7 | _ | |a pmid:40314736 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12638345 |2 pmc |
| 024 | 7 | _ | |a 1433-8491 |2 ISSN |
| 024 | 7 | _ | |a 0003-9373 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01313 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kurz, Carolin |0 P:(DE-2719)9000176 |b 0 |
| 245 | _ | _ | |a Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome. |
| 260 | _ | _ | |a Heidelberg |c 2025 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1764679643_28227 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Blood-based biomarkers (BBBMs) could significantly facilitate the diagnosis of Alzheimer's disease (AD) and non-AD dementia by providing less invasive alternatives to cerebrospinal fluid (CSF) and positron emission tomography (PET) imaging.This study investigated how well the BBBMs-amyloid-β (Aβ) 1-42/1-40 ratio, phosphorylated tau181 (pTau181), apolipoprotein E4 (ApoE4), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)-reflect thorough clinical work-up validated by PET and CSF biomarkers in participants with AD (n = 27), Aβ-negative CBS (n = 26), and agematched healthy controls (HC) (n = 17).Factor and correlation explored biomarker associations. Bayesian regression, backward selection regression, and ROC curve analysis were applied to identify optimal biomarker combinations and diagnostic cut-offs.In AD cases, pTau181 and ApoE4 levels were elevated, and the Aβ1-42/1-40 ratio was reduced. ROC analysis showed high accuracy for pTau181, ApoE4 and Aβ1-42/1-40 in discriminating AD from HC, with a combination significantly improving performance. However, limited fold change, and high variability reduced the diagnostic applicability of Aβ1-42/1-40 ratio. Elevated NfL levels were the most reliable biomarker for CBS-Aβ(-) cases. GFAP showed limited discriminatory power due to overlapping levels, suggesting that it may not serve as a disease-specific biomarker but may be indicative of general neurodegeneration.This study highlights the diagnostic utility of pTau181, ApoE4 and the Aβ1-42/1-40 ratio for AD and NfL in the CBS-Aβ(-) cases and emphasizes the added value of combined biomarker models for group differentiation. Prospective studies will help validate these findings and refine clinical thresholds. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 351 - Brain Function (POF4-351) |0 G:(DE-HGF)POF4-351 |c POF4-351 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Apolipoprotein E (ApoE4) |2 Other |
| 650 | _ | 7 | |a Beta-amyloid 1-40 (Aβ1-40) |2 Other |
| 650 | _ | 7 | |a Beta-amyloid 1-42 (Aβ1-42) |2 Other |
| 650 | _ | 7 | |a Glial fibrillary acidic protein (GFAP) |2 Other |
| 650 | _ | 7 | |a Neurofilament light chain (NfL) |2 Other |
| 650 | _ | 7 | |a Non-Alzheimer's disease dementia; beta |2 Other |
| 650 | _ | 7 | |a Phosphorylated tau (pTau) |2 Other |
| 650 | _ | 7 | |a tau Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Amyloid beta-Peptides |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a Peptide Fragments |2 NLM Chemicals |
| 650 | _ | 7 | |a Glial Fibrillary Acidic Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a Neurofilament Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Apolipoprotein E4 |2 NLM Chemicals |
| 650 | _ | 7 | |a amyloid beta-protein (1-42) |2 NLM Chemicals |
| 650 | _ | 7 | |a neurofilament protein L |2 NLM Chemicals |
| 650 | _ | 7 | |a GFAP protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a amyloid beta-protein (1-40) |2 NLM Chemicals |
| 650 | _ | 7 | |a MAPT protein, human |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: blood |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: diagnosis |2 MeSH |
| 650 | _ | 2 | |a tau Proteins: blood |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides: blood |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: blood |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Peptide Fragments: blood |2 MeSH |
| 650 | _ | 2 | |a Glial Fibrillary Acidic Protein: blood |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Neurofilament Proteins: blood |2 MeSH |
| 650 | _ | 2 | |a Neuroinflammatory Diseases: blood |2 MeSH |
| 650 | _ | 2 | |a Apolipoprotein E4: blood |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 650 | _ | 2 | |a Corticobasal Degeneration: blood |2 MeSH |
| 650 | _ | 2 | |a Corticobasal Degeneration: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Positron-Emission Tomography |2 MeSH |
| 700 | 1 | _ | |a Carli, Laura |b 1 |
| 700 | 1 | _ | |a Guersel, Selim |0 P:(DE-2719)9001027 |b 2 |u dzne |
| 700 | 1 | _ | |a Schrurs, Isabelle |b 3 |
| 700 | 1 | _ | |a Jethwa, Alexander |b 4 |
| 700 | 1 | _ | |a Carboni, Margherita |b 5 |
| 700 | 1 | _ | |a Bittner, Tobias |b 6 |
| 700 | 1 | _ | |a Hortsch, Sayuri |b 7 |
| 700 | 1 | _ | |a Keeser, Daniel |b 8 |
| 700 | 1 | _ | |a Brendel, Matthias |0 P:(DE-2719)9001539 |b 9 |u dzne |
| 700 | 1 | _ | |a Burow, Lena |b 10 |
| 700 | 1 | _ | |a Haeckert, Jan |b 11 |
| 700 | 1 | _ | |a Koriath, Carolin A M |b 12 |
| 700 | 1 | _ | |a Tatò, Maia Lucia |0 P:(DE-2719)9003524 |b 13 |u dzne |
| 700 | 1 | _ | |a Utecht, Julia |b 14 |
| 700 | 1 | _ | |a Papazov, Boris |b 15 |
| 700 | 1 | _ | |a Morenas Rodriguez, Estrella |0 P:(DE-2719)2812759 |b 16 |
| 700 | 1 | _ | |a Pogarell, Oliver |b 17 |
| 700 | 1 | _ | |a Palleis, Carla |0 P:(DE-2719)9000852 |b 18 |u dzne |
| 700 | 1 | _ | |a Weidinger, Endy |0 P:(DE-2719)9000882 |b 19 |u dzne |
| 700 | 1 | _ | |a Stöcklein, Sophia |0 P:(DE-2719)9003671 |b 20 |u dzne |
| 700 | 1 | _ | |a Levin, Johannes |0 P:(DE-2719)2811659 |b 21 |u dzne |
| 700 | 1 | _ | |a Höglinger, Günter |0 P:(DE-2719)2811373 |b 22 |u dzne |
| 700 | 1 | _ | |a Rauchmann, Boris-Stephan |0 P:(DE-2719)9001808 |b 23 |u dzne |
| 700 | 1 | _ | |a Perneczky, Robert |0 P:(DE-2719)2812234 |b 24 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1007/s00406-025-02013-z |g Vol. 275, no. 8, p. 2255 - 2273 |0 PERI:(DE-600)2793981-9 |n 8 |p 2255 - 2273 |t Archiv für Psychiatrie und Nervenkrankheiten |v 275 |y 2025 |x 1433-8491 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/282550/files/DZNE-2025-01313.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/282550/files/DZNE-2025-01313.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:282550 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)9001027 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 9 |6 P:(DE-2719)9001539 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 13 |6 P:(DE-2719)9003524 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2812759 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)9000852 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 19 |6 P:(DE-2719)9000882 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 20 |6 P:(DE-2719)9003671 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 21 |6 P:(DE-2719)2811659 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 22 |6 P:(DE-2719)2811373 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 23 |6 P:(DE-2719)9001808 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 24 |6 P:(DE-2719)2812234 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-351 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Brain Function |x 1 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-05 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-05 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 920 | 1 | _ | |0 I:(DE-2719)5000022 |k AG Dichgans |l Vascular Cognitive Impairment & Post-Stroke Dementia |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1111015 |k Clinical Research (Munich) |l Clinical Research (Munich) |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1110008 |k AG Simons |l Molecular Neurobiology |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)1111016 |k AG Levin |l Clinical Neurodegeneration |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000022 |
| 980 | _ | _ | |a I:(DE-2719)1111015 |
| 980 | _ | _ | |a I:(DE-2719)1110008 |
| 980 | _ | _ | |a I:(DE-2719)1111016 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|